Protective Effect of a Mitochondria-Targeted Peptide against the Development of Chemotherapy-Induced Peripheral...

Area of Science:

• Neuroscience
• Pharmacology
• Mitochondrial Biology

Background:

• Chemotherapeutic agents can cause dose-limiting peripheral neuropathy, negatively impacting patient quality of life and treatment adherence.
• Mitochondrial dysfunction is increasingly recognized as a key mechanism underlying chemotherapy-induced peripheral neuropathy (CIPN).
• SS-20 is a novel peptide designed to target mitochondria, enhance respiration, and restore cellular bioenergetics.

Purpose of the Study:

• To investigate the potential protective effects of SS-20 against oxaliplatin-induced peripheral neuropathy.
• To evaluate SS-20's efficacy in a preclinical murine model of CIPN.

Main Methods:

• A murine model was established using weekly oxaliplatin administration to induce peripheral neuropathy.
• Mice received continuous administration of SS-20 alongside oxaliplatin treatment.
• Neuropathic pain and intraepidermal nerve fiber density in the hind paw were assessed to evaluate neuropathy development and SS-20's effect.

Main Results:

• Oxaliplatin treatment successfully induced peripheral neuropathy, characterized by neuropathic pain and significant loss of intraepidermal nerve fibers.
• Continuous SS-20 administration significantly protected against the development of oxaliplatin-induced neuropathic pain.
• SS-20 treatment mitigated the loss of intraepidermal nerve fibers, restoring them to normal levels.

Conclusions:

• SS-20 demonstrates significant protective effects against chemotherapy-induced peripheral neuropathy in a preclinical model.
• The findings support SS-20's potential as a therapeutic candidate for preventing or treating CIPN.
• Targeting mitochondrial function with peptides like SS-20 offers a promising strategy for managing chemotherapy side effects.